Chronic pain, and particularly recurrent headaches like migraines, represents one of the most complex challenges for the modern healthcare system. Millions of people live with episodes that alter their quality of life, limiting daily activities and causing significant suffering. Given the insufficient response to certain conventional drugs—non-steroidal anti-inflammatory drugs, antiepileptics, or serotonin modulators—many patients seek alternatives. Cannabis has emerged in this context as an option discussed both for its historical use and for recent anecdotal reports.
In brief
- Limited evidence: There are no large clinical trials confirming the efficacy of cannabis specifically for migraines, unlike other conditions such as chemotherapy-induced nausea.
- Observational data: A recent study in the United States suggests a significant reduction in the frequency and severity of attacks in regular users under medical supervision.
- Route of administration: Inhalation (vaporization) appears more suitable than oral ingestion for acute management due to the speed of effect and lower risk of accidental overdose.
- Inherent risks: Unregulated consumption can induce secondary headaches or worsen the condition in some psychiatric profiles.
- Comprehensive approach: Migraine requires a multifactorial approach that includes sleep, stress, and diet, beyond the use of any psychoactive substance.
History and cultural context
Interest in hemp in medicine dates back centuries. During the 19th century, its use was documented to treat various pains, including menstrual headaches. The anecdote about Queen Victoria of England is frequently cited as proof of efficacy, although it lacks rigorous historical verification. However, medical records from the end of the 19th century, such as those published in The Lancet, reflected a positive perception of its analgesic properties when administered with caution.
This tradition has fueled the popular belief that cannabis is a universal remedy for pain. However, the pathophysiology of migraine is complex and involves specific neurovascular and genetic mechanisms that do not always respond to the same general analgesic principles.
What does current science say?
Unlike conditions such as neuropathic pain or chemotherapy-induced nausea, where there are multiple placebo-controlled studies on cannabinoids, the evidence for migraine is scarce. Most data come from uncontrolled clinical observations.
A relevant study recently published in Pharmacotherapy, conducted by researchers at the University of Colorado, offers an interesting perspective from an observational approach. They evaluated 121 adults who used medical cannabis under a prescription to prevent or treat migraine attacks.
The results indicated a notable reduction in the frequency of episodes: the average went from approximately ten monthly attacks to fewer than five. Furthermore, 48% of participants reported subjective improvements in both pain intensity and the duration of the crises.
It is crucial to understand that this study was not a randomized, placebo-controlled clinical trial, but a retrospective survey. Although the data are promising, they lack the rigor necessary to establish definitive causality or determine universal optimal doses.
Mechanisms of action and pathophysiology
A migraine is not simply a “headache”; it involves activation of the trigeminovascular system, release of neuropeptides such as substance P and CGRP, and central sensitization. Cannabinoids interact with the endocannabinoid system, which regulates functions such as pain, inflammation, and mood.
Theoretically, the modulation of these receptors could attenuate the neuronal hyperexcitability associated with crises. However, individual response varies enormously depending on the genetic profile, the composition of the extract (THC/CBG ratio), and the tolerance developed.
Routes of administration: safety and efficacy
The choice of how to consume cannabis is decisive for its utility in migraine. The oral route (edibles, infusions) presents significant problems:
- Irregular absorption: Hepatic metabolism converts cannabinoids into metabolites that are less potent but longer-lasting, which hinders precise control of the effect.
- Risk of overdose: It is easy to ingest excessive doses without perceiving immediate effects, causing anxiety or prolonged sedation.
Conversely, the intrapulmonary route (vaporized) offers clear advantages in this context:
- Speed of action: Effects appear in minutes, which is crucial for interrupting an incipient crisis.
- Controlled dose: It allows for adjusting the inhaled amount as needed.
- Lower toxicity: By avoiding the combustion of plant material, emissions of tars and other toxic compounds associated with traditional smoke are reduced.
However, consumption by inhalation carries respiratory risks if not performed with appropriate devices (vaporizers) and in controlled environments.
Harm reduction: a critical reading
Although some patients report benefits, it is imperative to address potential adverse effects. Chronic cannabis use can cause:
- Medication-overuse headache: In certain cases, regular consumption generates dependence and headaches upon cessation.
- Psychiatric symptoms: Anxiety, paranoia, or cognitive impairment in predisposed individuals.
- Tolerance: The need to increase doses to achieve the same analgesic effect.
Furthermore, not all patients respond the same way. What works for one may be ineffective or counterproductive for another. Self-medication without medical supervision is especially dangerous in complex neurological conditions.
Towards evidence-based medicine
The scientific community advocates for randomized clinical trials that compare synthetic cannabinoids or standardized extracts with placebos and standard treatments. Only then will we be able to define safe protocols, effective doses, and candidate patient profiles.
In the meantime, healthcare professionals must approach these consultations with intellectual honesty: acknowledging what we know (positive observational data), admitting what we do not know (lack of controlled trials), and always prioritizing patient safety over unrealistic expectations.
Editorial conclusion
Cannabis could have an adjuvant role in the management of refractory migraine, but not as a panacea. Its use must be integrated into a global strategy that includes lifestyle prevention, non-pharmacological therapies, and conventional medication when possible.
At Psiconáutica.org, we defend a sober, scientific, and human approach: neither demonizing nor idealizing psychoactive substances. Medical truth resides in data, not in internet stories or oral tradition. If you suffer from migraines and are considering this option, consult your neurologist or medical specialist to evaluate risks, benefits, and available alternatives.
Mental and physical health are indivisible; the path to pain relief requires patience, knowledge, and, above all, prudence.
